	Accroved for use discuss 10/31/99. OMB 0651-0031 Peters and Trecement Office: U.S. DEPARTMENT OF COMMERCE Peters and Trecement U.S. DEPARTMENT OF COMMERCE.			
	and restricted to respond to a construction to a			
Unx	REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)			
F	REQUEST FOR ACCESS OF ABANDON			
	QUEEN			
	RECEIVED - 071310 252 2/13/99			
	SEP 0 6 2001 Group Art Unit Examiner			
	File Information Unit			
	Paper No. #150			
	Assistant Commissioner for Patents Washington, DC 20231			
	seems to the secretarion file record of the above-			
I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE: — (A) referred to in United States Patent Number				
	paper number			
	inspection, i.e., Application from (D) an application in which the applicant has filed an authomation to lay open the complete application to the public.			
	application to the public. Please direct any correspondence concerning this request to the following address:			
	Vistella Pouralite 9-6-01			
	Signature RECHIVED			
	VIOLO VIA TOLACIA NOTE FOR PTO USE ONLY APPROVED DE 10 6 2001			
	(initials)			
	File Information Unit			

Takes of poursaled to take 0.2 hours to complete ins

United States Patent [19]

Queen et al.

[11] Patent Number:

5,585,089

[45] Date of Patent:

Dec. 17, 1996

[54] HUMANIZED IMMUNOGLOBULINS

- [75] Inventors: Cary L. Queen, Los Altos; Harold E. Selick, Belmont, both of Calif.
- [73] Assignee: Protein Design Labs, Inc., Mountain View, Calif.
- [21] Appl. No.: 477,728
- [22] Filed: Jun. 7, 1995

Related U.S. Application Data

- [63] Continuation of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,530,101, which is a continuation-in-part of Ser. No. 590, 274, Sep. 28, 1990, abandoned, and Ser. No. 310,252, Feb. 13, 1989, abandoned, which is a continuation-in-part of Ser. No. 290,975, Dec. 28, 1988, abandoned.

[56] References Cited

U.S. PATENT DOCUMENTS

4,578,335	3/1986	Urdal et al 530/351
4,816,397	3/1989	Boss et al 435/68
4,816,565	3/1989	Honjo et al 435/69.1
4,816,567		Cabilly et al 530/387
4,845,198		Urdal et al 530/387.3
4,867,973	9/1989	Goers et al
5,198,359	3/1993	Taniguchi et al 435/252.3
5,225,539	7/1993	Winter 530/387.3

FOREIGN PATENT DOCUMENTS

0171496	2/1986	European Pat. Off C12N 15/00
0173494	3/1986	European Pat. Off C12N 15/00
0184187	6/1986	European Pat. Off C12N 15/00
0256654	7/1987	European Pat. Off.
0239400	9/1987	European Pat. Off
0266663	6/1988	European Pat. Off C12N 15/00
2188941	10/1987	United Kingdom C12N 5/00
86/05513	9/1986	WIPO C12N 15/00
87/02671	5/1987	WIPO C07H 15/12
89/01783	3/1989	WIPO A61K 39/395

OTHER PUBLICATIONS

Riechmann et al. Nature vol. 332 24, Mar. 1988 p. 323. Foote, Nova Acta Leopoldina 1989. vol. 61 (269) 103. Amit et al. Science vol. 233 1986 p. 747.

Groves et al. vol. 6, 1987, p. 71.

Better et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment", Science 240:1041-1043 (1988).

Bird et al., "Single-Chain Antigen-Binding Proteins", Science 242:423-426 (1988).

Boulianne et al., "Production of functional chimeric mouse/ human antibody," *Nature* 312:643-646 (1984).

Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy," *Proc. Natl. Acad. Sci.* 89:4285-4289 (1992).

Chothia, C. and A. M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins", *J. Mol. Biol.* 196:901–917 (1987).

Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci. USA* 88:2869–2873 (1991).

Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," *J. of Immunol.* 148(4):1149–1154 (1992).

Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids Res.* 19:2471-2476 (1991).

Ellison et al., "The nucleotide sequence of a human immunoglobulin C(gamma)₁gene", *Nucleic Acids Res.* 10:4071–(1982).

Farrar, J., "The biochemistry, biology, and role of interleukin-2 in the induction of cytotoxic T cell and antibodyforming B cell receptors," *Immunol. Rev.* 63:129-166 (1982).

Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.* 224:487–499 (1992).

Gorman et al., "Reshaping a therapeutic CD4 antibody," Proc. Natl. Acad. Sci. 88:4181-4185 (1991).

Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and Its Cellular receptor", in *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York (1986) pp. 283–301.

Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H", *Lancet* Dec. 17, 1988, pp. 1394-1399.

Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments", Cell 22:197-207 (1980).

(List continued on next page.)

Primary Examiner—Lila Feisce
Attorney, Agent, or Firm—Townsend and T

Attorney, Agent, or Firm-Townsend and Townsend and Crew LLP

[57] ABSTRACT

Novel methods for producing, and compositions of humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that arc, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 A as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.